Immunic, Inc.
IMUXImmunic, Inc. is a late-stage biotechnology company focused on developing oral, small molecule therapies for chronic inflammatory and autoimmune diseases.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
Profile
Immunic, Inc. is a late-stage biotechnology company focused on developing oral, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's primary value proposition lies in its clinical-stage pipeline targeting neurologic and gastrointestinal conditions, specifically multiple sclerosis and celiac disease. Its lead programs utilize unique mechanisms of action, such as DHODH inhibition and Nurr1 activation, to provide neuroprotective and anti-inflammatory benefits.
A late-stage clinical developer with a unique dual-action mechanism (neuroprotection and anti-inflammation) in the competitive multiple sclerosis market.
FAQ
- What is Immunic, Inc.'s market cap?
- Immunic, Inc. (IMUX) has a market capitalization of $108.6M and trades on NASDAQ.
- Who are Immunic, Inc.'s competitors?
- Immunic, Inc.'s key competitors include Biogen Inc., Medicinova, Inc., Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Immunic, Inc. partner with?
- Immunic, Inc.'s notable partners include Fraunhofer Institute, Leerink Partners LLC, BVF Partners, L.P., and others.
- What subsidiaries does Immunic, Inc. have?
- Immunic, Inc.'s subsidiaries include Gliomic Therapeutics Inc., Immunic Australia.
- Where is Immunic, Inc. headquartered?
- Immunic, Inc. is headquartered in United States of America and employs approximately 80 people. It has been publicly traded since 2014.